Pralidoxime Chloride Auto-Injector

(pralidoxime chloride injection)

 
 

You Are Now Leaving the MeridianMeds.com Website

Links to other sites are provided as a convenience to the viewer.

Pfizer accepts no responsibility for the content of linked sites.

CANCEL
Product image Mobile: 

For optimal reactivation of organophosphate-inhibited cholinesterase, atropine and pralidoxime should be administered as soon as possible after exposure. As an adjunct to atropine, the Pralidoxime Chloride Auto-Injector helps treat muscle weakness and respiratory depression that can occur following a nerve agent attack.9

Product indication: 

Indication:

This auto-injector for pralidoxime chloride is specifically indicated for intramuscular use as an adjunct to atropine in the treatment of poisoning by nerve agents having anticholinesterase activity.

 

Product Especification: 
To order or request a quote, call 1-800-638-8093
Key Product Specifications10:
NSN6505-01-125-3248
NDC11704-251-01
Delivers600 mg pralidoxime chloride in 2 mL
Length of Unit144 mm
Diameter of Unit19 mm
Needle Gauge22
Needle Length21 mm
Administration TypeIntramuscular injection
Packaged100 auto-injectors per box; package inserts
Packaging for Shipping100 units per box (327 mm x 298 mm x 191 mm), weighing 5.9 kg

2 interior boxes (200 units) per shipper box (613 mm x 343 mm x 210 mm), weighing 11.8 kg
StorageStore at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [See USP Controlled Room Temperature]. Keep from freezing.
Prescription RequiredYes
For medical: 

For medical questions concerning Meridian products, to report an adverse event, or to speak to a member of Pfizer US Medical Information, call 1-800-438-1985.

Important Safety Information and Indication
IMPORTANT SAFETY INFORMATION AND INDICATION

Pralidoxime Chloride Auto-Injector (pralidoxime chloride injection)

The pralidoxime chloride auto-injector is contraindicated in patients who are hypersensitive to any component of the product.

Pralidoxime is not effective in the treatment of poisoning due to phosphorus, inorganic phosphates, or organophosphates not having anticholinesterase activity.

Because pralidoxime is excreted in the urine, a decrease in renal function will result in increased blood levels of the drug. Thus, the dosage of pralidoxime should be reduced in the presence of renal insufficiency.

The pralidoxime chloride auto-injector should be self- or buddy-administered by military personnel or administered by qualified civilian emergency responders only after the individual has donned his mask and ensured that some or all of the symptoms of nerve agent poisoning are present.

It is also not known whether pralidoxime can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Pralidoxime should be administered to a pregnant woman only if clearly needed.

Mild to moderate pain may be experienced at the site of injection. Pralidoxime may cause blurred vision, diplopia and impaired accommodation, dizziness, headache, and drowsiness, among other symptoms.

Indication:

This auto-injector for pralidoxime chloride is specifically indicated for intramuscular use as an adjunct to atropine in the treatment of poisoning by nerve agents having anticholinesterase activity.